A Phase II, Open-Label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults using FBS0701 (SSP-004184 ).

Measure the extent and durability of FBS0701 treatment effects; continue to assess the safety, tolerability and efficacy of FBS0701 (SSP-004184) in subjects who received FBS0701(SSP-004184) in prior Ferrokin sponsored study; allow access and assess response to FBS0701 (SSP-004184) in subjects randomised to another chelating therapy in a prior FerroKin-sponsored FBS0701(SSP-004184) study.